Nuvaxovid Sales was Novavax’s largest product and service line in fiscal 2025, bringing in $625.18M of $1.12B (56%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product Sales | — | — | $213.20M | — | ||||||
| Product Revenue | $1.55B | — | — | — | ||||||
| Nuvaxovid Sales | — | $531.39M | — | $625.18M | ||||||
| Grants | $382.92M | $427.32M | — | — | ||||||
| Grants & Other | — | — | — | — | ||||||
| Grant & Other | — | — | — | — | ||||||
| Licensing, Royalties, & Other | $43.99M | $8.49M | $468.96M | $438.44M | ||||||
| Royalties & Other | — | — | — | — | ||||||
| Supply Sales | — | $16.50M | — | $59.86M | ||||||
| Milestone Payments | $20.00M | — | — | — | ||||||
| Sales-Based Royalties | $9.00M | — | — | — | ||||||
| Government Contract | — | — | — | — | ||||||
| Total | $2.01B | $983.71M | $682.16M | $1.12B |
Novavax brought in $1.12B from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Novavax regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $682.16M. Nuvaxovid Sales was the largest at $625.18M (55.6%), ahead of Licensing, Royalties, & Other at $438.44M (39.0%) and Supply Sales at $59.86M (5.3%).
Novavax began breaking out Nuvaxovid Sales in fiscal 2023 and Supply Sales in fiscal 2023. Novavax stopped reporting Product Revenue ($1.55B in fiscal 2022), Grants ($427.32M in fiscal 2023), Product Sales ($213.20M in fiscal 2024) and two others as separate lines.
Novavax (NVAX) reports its revenue by product and service. In fiscal 2025, Nuvaxovid Sales was its largest product and service line, bringing in $625.18M (55.6% of the total), followed by Licensing, Royalties, & Other at $438.44M (39.0%).
Nuvaxovid Sales was Novavax's largest product and service line in fiscal 2025, bringing in $625.18M, or 55.6% of the $1.12B total across its three product and service lines.
Every figure comes from Novavax's annual financial filings, as reported. Each line keeps the name Novavax gives it, and years follow its fiscal calendar.
Novavax's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.